Last reviewed · How we verify
NCT07099456: CALLIOPE
Fertility And Sexual Function In CAH: CALLIOPE
trial in Congenital Adrenal Hyperplasia (CAH) in 50 participants. Currently enrolling.
1 November 2029
Quick facts
| Lead sponsor | University of Roma La Sapienza |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 November 2024 |
| Primary completion | 1 November 2029 |
| Estimated completion | 1 November 2030 |
| Sites | 1 location across Italy |
Conditions studied
- Congenital Adrenal Hyperplasia (CAH) — all drugs for Congenital Adrenal Hyperplasia (CAH) →
Sponsor
University of Roma La Sapienza
Who can join
Adults 18 to 65, any sex, with Congenital Adrenal Hyperplasia (CAH). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter study designed to assess the effects of groundbreaking CAH therapies on a spectrum of clinical and biochemical outcomes, with a special emphasis on reproductive and sexual health. Fertility is a profound concern for individuals with CAH, given the high prevalence of gonadal dysfunction that arises from the hormonal derangements that characterize this complex disease. At our endo-ERN accredited center for rare diseases at Policlinico Umberto I, addressing these fertility issues in CAH patients represents a daily commitment. The revolution of the pharmacological management of CAH is one of the most debated topics to date. Data on the effects of novel management options for CAH on fertility are scarce, but the anecdotal improvements in sperm count and menstrual regularity reported in the latest clinical trials have significantly motivated us to design the CALLIOPE study. Thus, we aim to delve deeper into the fertility and sexual function of CAH patients, employing advanced seminal parameter evaluations, multiparametric gonadal ultrasound, and sophisticated hormonal analyses in both females and males performed by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Beyond fertility, the CALLIOPE trial aspires to provide further understanding of therapy's effects on body composition, metabolism, immune function, coagulation, and quality of life, among other factors. We will explore the immunological impact of novel CAH therapies by quantifying Peripheral Blood Mononuclear Cells (PBMCs) and analyzing transcriptomic profiles to unveil gene expression patterns and identify biomarkers that could signal therapeutic targets or disease management strategies in CAH. Moreover, seminal plasma will be used to assess the expression of adrenal miRNAs regulating steroidogenesis and metabolism. The research will be conducted at our rare disease referral center (Policlinico Umberto I, Sapienza University of Rome) in collaboration with leading centers across Italy: Modena (Università degli Studi di Modena e Reggio Emilia), Naples (Università Federico II), Rome (Ospedale Sant'Andrea) and Bologna (Alma Mater Studiorum - Università di Bologna). https://isidorilab.com/home
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07099456
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Congenital Adrenal Hyperplasia (CAH)
Currently open trials in the same condition.
- NCT07473804 — Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC) · recruiting
- NCT00250159 — Natural History Study of Patients With Excess Androgen · recruiting
Other University of Roma La Sapienza trials
Trials by the same sponsor.
- NCT07485023 — Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation · NA · not yet recruiting
- NCT07305519 — The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin · NA · not yet recruiting
- NCT07520968 — ABX Versus CHX in NSPT: a RCT · NA · active not recruiting
- NCT07109596 — Integration of Clinical, Biological and Psycho-social Variables for a Gender-sensitive Frailty Prediction · recruiting
- NCT07490574 — Trial of Underwater Versus Gas-Insufflation Colorectal Endoscopic Submucosal DisseEtion · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07099456 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Roma La Sapienza
- Last refreshed: 1 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07099456.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing